Technological Elevation To Drive The Renal Anemia Treatment Market

Posted by Merin John on May 5th, 2021

Rise in the prevalence of chronic kidney disease is the key factor responsible for the growth of Renal Anemia Treatment market. According to a latest research by Persistence Market Research (PMR), the global Renal Anemia Treatment market is anticipated to have accounted for US$ 4,115.0 Mn, in terms of value, during 2017. The report on Renal Anemia Treatment further projects significant growth potential with average year-on-year growth rate pegged at 7.5% over the period of 2018-2026.

Renal Anemia Treatment Market: Key Dynamics

The global burden of chronic kidney disease continues to increase throughout the globe, which is driving the growth of the renal anemia treatment market. According to the National Kidney Foundation, 10% of the population worldwide is affected by the chronic kidney disease (CKD), which in turn, has increased the patient pool for renal anemia treatment.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/27115

Company Profile

Amgen Inc.

Vifor Pharma Management Ltd.

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Sandoz International GmbH (Novartis AG)

Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Teva Pharmaceutical Industries Ltd.

AMAG Pharmaceuticals

Rockwell Medical

Akebia Therapeutics

Increasing cases of chronic kidney disease and increasing prevalence of diabetes and hyper tension will push the market of renal anemia treatment in near future. Additionally, the development and identification of novel HIF stabilizers is likely to change the pathway for renal anemia treatment in near future.

HIF stabilizers under clinical trial hold promise as they provide a unique modality for renal anemia treatment through novel mechanisms of action. There are currently 4 HIF stabilizers that are in phase 2/3 clinical trials (roxadustat, daprodustat, vadadustat, and molidustat) and all of these are orally administered agents which will create huge opportunities for the growth of the renal anemia treatment market during the forecast period.

On the other side, drugs for renal anemia treatment come with a huge price tag. Even the good health insurance benefits do not necessarily cover biologics and thus, the out-of-pocket expenditure is too high. High cost for renal anemia treatment is, thus, the biggest factor that limits the treatment seeking rate with biologics and in turn, negatively impacts the growth of the renal anemia treatment market.